Clinical Trial Update: Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer [Phase 3]

View source ↗

Summary

Phase 3 study of Zoptarelin Doxorubicin (AEZS-108) as second-line therapy for endometrial cancer has completed. Results have been posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Zoptarelin Doxorubicin (AEZS-108 (zoptarelin doxorubicin))

Snippet

Sponsor: AEterna Zentaris | Conditions: Endometrial Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-07-31